JPM execs speak on 2018: Pricing moves, yes. M&A frenzy, no by Tracy Staton Monday, January 15, 2018 The J.P. Morgan Healthcare Conference was a great place to suss out the general biopharma mood as 2018 begins.
After Prostvac flop, Bavarian Nordic showcases RSV data by Angus Liu Monday, September 25, 2017 After a major cancer vaccine misstep, Bavarian Nordic reported positive six-week data from an ongoing phase 2 study on its RSV vaccine candidate.
Bavarian Nordic posts positive phase 2 for universal RSV shot by Angus Liu Tuesday, June 27, 2017 Chasing a $6 billion market opportunity, Bavarian Nordic reports that a dose of its universal RSV vaccine can elicit a significant immune response.
